Skip to main content
. 2020 Jul 30;8(2):e000691. doi: 10.1136/jitc-2020-000691

Figure 5.

Figure 5

CLEC9A-NY-ESO-1 primes naïve NY-ESO-1-specific T cells in humanized mice. (A) Experiment schematic. (B) Percentage of NY-ESO-1 SLL-specific CD8+ T cells measured by SLL dextramer 1 week after priming in vivo. Each point represents splenocytes from individual humanized mice. (C) Interferon γ (IFNγ) production by splenocytes from vaccinated mice following ex vivo stimulation with SLL peptide. Data are the combined replicates from three independent experiments, shown as IFNγ spot forming units (SFU) per 50,000 human CD45+ splenocytes. *p=0.005, **p=0.003, ***p=0.002 (two-way analysis of variance and Tukey’s multiple comparison test). Ab, antibody; NY-ESO-1, New York esophageal squamous cell carcinoma 1; poly I:C, polyinosinic:polycytidylic acid.